stars 1 stars 2 stars 3

Founded in 2012 at the University Galway, Ireland, Aquila Bioscience's focus is to develop nature inspired safe and environmentally sustainable technologies to protect humans and animals from pathogens. Aquila Bioscience's Pathogen Capture Technology (PCT) was developed in collaboration with the Defence Forces Ireland and the Czech University of Defence to protect first responders against biothreat agents. It has been demonstrated to be effective against a number of bacteira, viruses, fungi and biotoxins that pose threat to human and animal health. Aquila Bioscience have successfully applied this technology and launched the first Aquila Bioscience product, “ABD device”. It is free from alcohol and toxic chemicals, and is a biodegradable Class I device that safely captures, removes and neutralizes harmful pathogens and viral infections like coronavirus from the skin including eyes nose and mouth plus sensitive and hard surfaces such as screens, workbenches, desks etc. Our experienced R&D team bring together a range of science disciplines, bridging Glycobiology, Immunology, Microbiology, biochemistry and analytical chemistry.

Aquila Bioscience Questions

The Aquila Bioscience annual revenue was $205000 in 2026.

Lokesh Joshi is the Founder of Aquila Bioscience.

4 people are employed at Aquila Bioscience.

The NAICS codes for Aquila Bioscience are [5417, 54, 54171, 541, 541714].

The SIC codes for Aquila Bioscience are [873, 87].

Top Aquila Bioscience Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users